Clinical Trial

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

Name: Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor — clinical trial record (NCT07238712)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: APTBCy

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Optimization of bendamustine-containg graft-versus-host disease (GVHD) prophylaxis to reduce the incidence of secondary haemophagocytic lymphohistiocytosis and GVHD

Trial Details

NCT Number	NCT07238712
Lead Sponsor	St. Petersburg State Pavlov Medical University
Conditions	Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia, Myelodysplastic Syndromes (MDS), Myeloprolipherative Neoplsm, Atypical Chronic Myeloid Leukemia
Enrollment	60 participants
Start Date	2025-05-10
Primary Completion	2026-12-10 (estimated)
Study Completion	2026-12-10 (estimated)
Updated on ClinicalTrials.gov	2025-11-20